<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Geuka Africa | Glenn Dresner | Activity</title>
	<link>https://geuka.org/members/glenndresner/activity/</link>
	<atom:link href="https://geuka.org/members/glenndresner/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Glenn Dresner.</description>
	<lastBuildDate>Mon, 01 Jun 2026 05:33:33 +0000</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">2c6aa33cbfbf872cf9c0217270b916f6</guid>
				<title>Glenn Dresner started the topic JWH-210 CHEMICAL POWDER in the forum Basic Home Budgeting</title>
				<link>https://geuka.org/forums/topic/jwh-210-chemical-powder-5/</link>
				<pubDate>Sun, 31 May 2026 20:51:43 +0000</pubDate>

									<content:encoded><![CDATA[<p>4. Drugs<br />
In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the&hellip;<span class="activity-read-more" id="activity-read-more-205760"><a href="https://geuka.org/forums/topic/jwh-210-chemical-powder-5/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">43adf5fa9f32c35ac031365cf6726a1f</guid>
				<title>Glenn Dresner started the topic Clinical features associated with ADB-BUTINACA exposure in patients attending. in the forum Basic Home Budgeting</title>
				<link>https://geuka.org/forums/topic/clinical-features-associated-with-adb-butinaca-exposure-in-patients-attending/</link>
				<pubDate>Tue, 26 May 2026 07:23:33 +0000</pubDate>

									<content:encoded><![CDATA[<p>All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak&hellip;<span class="activity-read-more" id="activity-read-more-204422"><a href="https://geuka.org/forums/topic/clinical-features-associated-with-adb-butinaca-exposure-in-patients-attending/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
		
	</channel>
</rss>